

## REVIEW

# Should we consider the infusion of lipid emulsion in the resuscitation of poisoned patients?

Grant Cave<sup>1\*</sup> and Martyn G Harvey<sup>2</sup>

### Abstract

The use of intravenous lipid emulsions (ILEs) as antidote in local anaesthetic systemic toxicity has gained widespread support following convincing data from animal models, and successful case reports in humans. Proposed beneficial mechanisms of action for ILEs include intravascular sequestration of intoxicant and subsequent enhanced redistribution to biologically inert tissues, augmentation of fatty acid utilisation for ATP synthesis in the context of metabolic poisoning, and direct cardiotoxic and ion channel effects. The evidence base for use of ILEs in acute drug intoxication is evolving. The present evidence supports use of ILEs only in local anaesthetic systemic toxicity and in lipophilic cardiotoxin intoxication when there is an immediate threat to life, and other therapies have proven ineffective.

### Introduction

Intravenous lipid emulsion (ILE) has a long history of use as a parenteral nutrition formulation in both adult and paediatric patients. Over the past decade, ILE also emerged as a novel treatment for iatrogenic and intentional drug poisonings. Progress from nutritional replacement to antidote has been rapid, necessitating regular review of the rationale and evidence base for administration.

As early as 1998 Weinberg and colleagues reported attenuation of bupivacaine toxicity in a rat model [1], following a chance finding while attempting to replicate local anaesthetic effects in disorders of carnitine metabolism. These findings were subsequently confirmed in intact dogs [2]. Still earlier findings of lipid modulation of free drug concentrations have been reported as far back as 1974 [3]. Promising laboratory studies such as

these may have forever lacked clinical impact but for two sentinel cases of ILE use in human poisoning.

In 2006 Rosenblatt and colleagues [4] reported successful resuscitation with ILE following bupivacaine and mepivacaine-induced cardiac arrest in a middle aged man undergoing brachial plexus block. Prior treatment with advanced cardiac life support, defibrillation, and multiple doses of vasopressor and antiarrhythmic medications had failed to effect return of spontaneous circulation. Normal sinus rhythm was nevertheless restored following one 100 ml bolus of ILE with rapid return of haemodynamic stability. The patient was discharged neurologically intact.

Likewise in 2007, Sirianni and colleagues [5] published a case of overwhelming bupropion and lamotrigine self poisoning in a 17 year old girl. Cardiovascular collapse refractory to standard resuscitative measures persisted for 70 minutes before administration of 100 ml ILE. Immediately after injection the patient exhibited a sustained stable circulation and survived to hospital discharge. These, the first case reports of successful ILE use in local anaesthetic systemic toxicity (LAST) and non-local anaesthetic intoxication, respectively, are unique for a number of reasons. In both instances attending physicians were presented with desperate and apparently irretrievable clinical scenarios secondary to poisoning. The decision to employ ILE was made late in the course of resuscitative attempts as a 'last gasp' measure, with only limited animal data to support utilisation. And, in both circumstances, use was associated with dramatic success and patient survival.

The dissemination of these and other subsequent cases of clinical use of ILE has seen ILE make the transition from bench-top modelling to clinically utilised antidote without the evidence base commonly associated with introduction of newly formulated drugs. There have been many recent systematic reviews on this topic of a high standard [6-10]. It is the purpose of the present narrative review to examine recent literature with a particular focus on advances in understanding of the mechanism of ILE, and to evaluate the evidence supporting ILE administration, and thereby establish whether any

\* Correspondence: [grantcave@gmail.com](mailto:grantcave@gmail.com)

<sup>1</sup>Department of Critical Care, Tamworth Rural Referral Hospital, Tamworth, NSW 2340, Australia

Full list of author information is available at the end of the article

changes to present recommendations for utilisation are warranted. PubMed was searched for the 5 years since the authors previous review [6], using the search terms intravenous AND fat emulsion OR lipid emulsion OR intralipid AND "toxicity" OR "resuscitation" OR "rescue" OR "arrest" OR "antidote" and a filter for relevance. Only English language papers were included.

### Rationale for use of intravenous lipid emulsion in toxicology

There are presently four small human trials involving the use of ILE: one clinical randomised controlled trial of limited methodologic quality, one case-control study and two pharmacokinetic evaluations. While this small body of human trial work is of importance, it is not sufficient to form a view on the use of ILE in toxicology. The weight of present data is in benchtop and animal models and collated human case reports. While it is possible to evaluate such an evidence base, there are clear limits to the breadth such evidence can generalise to everyday clinical practice.

In the setting of immediate threat to life where other treatments are not proving effective, it is reasonable to use an agent when there is an established rationale for use and 'all or nothing' cases such as those described above have been reported. Table 1 lists agents for which the criterion of positive benchtop evidence and reported clinical use associated with a positive outcome has been fulfilled.

**Table 1 Agents for which there is both positive benchtop evidence for class effect and reported clinical use associated with a positive outcome**

Na channel antagonists
Local anaesthetics [11-14]
Tricyclic antidepressants [9,15-24]
Doxepin
Imipramine
Amitriptyline
Dothiepin
Flecainide (benchtop model evidence equivocal)
Propafenone
Cocaine
Ca channel blockers [9,25-27]
Verapamil
Diltiazem
Beta blockers [9,28,29]
Propranolol
Carvedilol
Nebivolol
Miscellaneous [30,31]
Haloperidol

Given the above rationale, this paper first outlines the available laboratory evidence on mechanism of action of ILE as antidote, and then progresses to review reported clinical experience.

### Pharmacologic mechanism of action for intravenous lipid emulsion

Knowledge of the proposed pharmacologic mechanisms of action of ILE in acute intoxication is important when considering clinical application. Despite extensive and ongoing study the precise mode of action for ILE in many poisonings remains to be fully elucidated. At present both pharmacokinetic and pharmacodynamic actions have been postulated to play a role in the action of ILE as antidote. Whilst synergy between proposed actions may exist, the relative contributions of each remain uncertain. It is quite possible that each mechanism may variably contribute to clinically observed improvement depending on unique combinations of patient factors, the mode and duration since poisoning, and the particular intoxicant.

### Pharmacokinetic modulation/lipid sink theory

First forwarded by Weinberg in 1998 [1], this hypothesis proposes that, following ILE injection, lipophilic intoxicant preferentially distributes into the newly created intravascular lipid compartment, and is held away from the site of toxic action. The hypothesis has been extended to include effects on subsequent enhanced redistribution of lipophilic intoxicants, with increased blood carriage thought to speed transport of toxin from target organ to peripheral adipose tissue depots. This so called 'lipid sink' thesis has served to guide much of the early development of ILE therapy, with the majority of agents studied thus far exhibiting high lipid solubility.

Evidence in support of the lipid sink has been derived from both pre-clinical models and human reports. Following their study with the prototypical lipophilic local anaesthetic bupivacaine in whole rat models of cardiotoxicity [1], Weinberg and colleagues subsequently demonstrated enhanced myocardial washout of bupivacaine when cardiac perfusate was spiked with ILE in an isolated heart model [11]. Both greater myocardial bupivacaine loss ( $P < 0.0016$ ) and increased coronary sinus effluent bupivacaine concentration ( $P < 0.008$ ) were recorded, in keeping with rapid tissue detoxification. Similarly, Chen and colleagues [12] have shown lesser myocardial bupivacaine concentrations, and associated dose-dependent increases in rate-pressure product for isolated rat hearts subjected to lipid emulsion.

Subsequent authors investigating the effect of ILE injection in whole rats have demonstrated evidence of enhanced drug redistribution with reduced bupivacaine concentration in heart, brain, lung, kidney and splenic

tissue observed following ILE treatment [13]. The hepatic bupivacaine concentration was increased. In this model ILE use was associated with greater bupivacaine clearance, and prolonged half-life ( $T_{1/2}$ ) compared with control animals, in keeping with favourable modulation to bupivacaine pharmacokinetics.

Support for a lipid sink effect is not confined to lipophilic local anaesthetics, with animal models and human cases demonstrating an effect with a range of disparate intoxicants, including calcium channel blockers [25-27], lipophilic beta-blockers [28,29], tricyclic antidepressants [15-17], antipsychotics [30,31], and antiarrhythmics [32]. Despite lacking commonality in their toxicodynamic mechanisms, agents demonstrating response to ILE treatment typically exhibit high lipid solubility ( $\log D$  (octanol:water partition coefficient at physiologic pH)  $>2$ ; bupivacaine  $\log D = 3.65$ ), consistent with the proposed pharmacokinetic mechanism. Indeed, drug partitioning constants and volumes of distribution have been investigated as predictors of ILE responsiveness. French and co-workers in 2011 [33] demonstrated *in vitro* sequestration of lipophilic drugs in human plasma spiked with lipid emulsion, and subsequently assembled a compendium of predicted lipid extraction efficiency on the basis of the intrinsic pharmacologic parameters for over 50 commonly used drugs.

*In vivo* studies using non-local anaesthetic drugs have confirmed sink effects in intact animal models and human subjects. In a rabbit model of intravenous clomipramine toxicity, increased total blood concentrations of clomipramine were seen in concert with improved blood pressure following ILE injection, consistent with sequestration of toxin into an intravascular lipid phase [34]. Litonius and colleagues [35] similarly demonstrated an increased total amitriptyline concentration with a decrease in free amitriptyline fraction in amitriptyline toxic pigs when ILE was given after amitriptyline infusion. Notably, however, there was no improvement seen in haemodynamic metrics nor survival in this model. The same group furthermore demonstrated that pretreatment with ILE improved haemodynamics during an amiodarone infusion, and resulted in increased amiodarone total concentration and decreased free drug concentration [32]. ILE has also been shown to reduce brain concentrations of amitriptyline when given following intravenous infusion and tissue distribution time in swine [36]. In the same experiment a non-statistically significant reduction in cardiac amitriptyline concentrations was additionally reported ( $P = 0.07$ ).

Human pharmacokinetic data are limited to two clinical studies and sporadic case reports. Minton and colleagues [37] demonstrated a statistically non-significant increase in plasma amitriptyline concentrations in subjects in pharmacokinetic steady state subjected to infused lipid emulsion. Free drug concentrations were not measured. Litonius and

colleagues [38] furthermore found a decreased half-life for a nontoxic dose of bupivacaine in blood after administration of ILE in eight normal subjects, consistent with an effect on tissue redistribution. A decrease in free verapamil concentration was reported after treatment with ILE for intoxication [39], commensurate with clinical improvement. In another report, increased total blood amitriptyline concentrations were seen following ILE therapy in a case of mixed overdose with prominent tricyclic toxidrome [40].

While attractive in its simplicity, emerging evidence suggests application of the sink theory must be approached with some caution in all but a few overdose scenarios. A pure sink effect may be important in cardiac arrest due to direct intravenous bolus administration of intoxicant - the centralised circulation meaning that rapid equilibration of heart and brain concentrations with the introduced, centrally confined lipid phase may be possible. Subsequent redistribution of intoxicant to peripheral fat depots on return of effective circulation would conceivably ensue - such a situation could be hypothesized to occur in most forms of LAST.

Any pharmacokinetic effect for ILE in the non-arrested patient likely depends on both the pharmacokinetic phase and circulatory status at the time of intoxication. Increased plasma carriage for lipophilic toxins with ILE injection will increase drug transport between organ systems according to a complex interplay of tissue drug affinity, relative concentration, and perfusion. As such, net movement of intoxicant may not prove universally beneficial (that is, from target organ to peripheral depot). For example, in one study investigating the effect of ILE on thiopental anaesthesia in rabbits, early lipid administration appeared to increase the depth, but not overall duration, of anaesthesia. This could be explained by the action of lipid emulsion as a high affinity conduit - maintaining blood concentrations able to interact with the brain during early redistribution to hydrophilic tissues, before augmenting later redistribution from rapidly perfused to lesser perfused lipophilic tissues [41].

Perhaps most vexing is the issue of ILE administration following enteric overdose. Data suggesting that ILE injection may actually augment absorption of lipophilic toxins from the gastrointestinal lumen have emerged, with increased mortality reported when ILE was administered early in the course of oral amitriptyline and verapamil toxicity [42], and earlier death following ILE in rectal thiopentone overdose [43] in rodent models. Documented increases in plasma intoxicant concentrations were reported in both studies. Effects on enhanced gastrointestinal uptake are likely to be limited to the absorptive phase of intoxication. For example, when ILE was administered 5 minutes after oral poisoning with the lipophilic organophosphate parathion in rats, no difference was observed in time to respiratory arrest. When

given at 20 minutes (at the time of anticipated peak intravenous parathion concentration), ILE effected a significant increase in survival times, consistent with beneficial augmentation of drug redistribution [44].

The sum of what is known on the pharmacokinetic effects of ILE as antidote seems to be that there are demonstrable effects on absorption, distribution and redistribution for lipophilic intoxicants. Early ILE use in enteric poisoning may be contraindicated because of potential for enhancing gastrointestinal absorption, albeit any such adverse effect is likely dependent on adequate intestinal perfusion, and mitigated somewhat by development of shock-like states secondary to intoxication. The clinical corollary of this would be that effects on blood concentrations following ILE administration likely depend on the timing of administration relative to both the pharmacokinetic phase and the mode of intoxication. It would also seem prudent to ensure actions necessary to mitigate gastrointestinal absorption, such as activated charcoal, were taken before or contemporaneous to lipid emulsion.

#### **Direct cardiotoxic effect**

While clinical and experimental effects spanning agents and organ systems favour a pharmacokinetic mechanism as important in the action of ILE, they are not a complete explanation. Recent data have emerged that suggest lipid emulsions at the doses used have direct cardiotoxic effects. Experimentally, rats infused with lipid emulsion showed increased blood pressure and aortic flow rates relative to the same volume of saline. Additionally, isolated rat hearts in isovolumetric contraction were seen to contract more forcefully, with increased oxygen demand, when perfusate was augmented with lipid emulsion [45]. Stehr and colleagues [46] additionally demonstrated a positive effect on bupivacaine toxic cardiac myocytes at levels below those that could have effected any 'sink' phenomenon. The same investigators furthermore modelled the relative contributions of volume, sink and cardiotoxic effects in an *in silico* model for the observed effect on recovery of rats from bupivacaine-induced shock. The model of best fit included all three factors, with the direct cardiotoxic effect being the most prominent factor responsible for observed improvement [47].

It seems likely that direct cardiotoxic effects play a significant role as one of the mechanisms responsible for resuscitation from drug-induced cardiotoxicity. This may be particularly so in the arrested or critically compromised circulation in order to offer immediate support before any distributive effects are likely to occur.

#### **Fatty acid metabolism theory**

There is evidence that metabolic pathways influenced by lipid emulsion are important in the experimental mechanism of action of ILE. Partownavid and colleagues [48]

demonstrated failure of ILE rescue in rat bupivacaine toxicity in the presence of the inhibitor of fatty acid metabolism CTV. A dose-dependent relationship for CTV on both resuscitation outcome and measures of cardiac function post-resuscitation was additionally observed. In an associated laboratory experiment, bupivacaine toxic mitochondria were more resistant to external calcium pulses, thought to be a mechanism effecting cell death, when treated with ILE prior to extraction. Conversely, Bania and colleagues [49] reported no adverse effect for oxfenicine, a blocker of fatty acid transport into mitochondria, on survival time during verapamil infusion in whole rats.

While experimental data showing reduction in myocardial bupivacaine concentration post-ILE demonstrate that pharmacokinetic mechanisms play a role in ILE resuscitation, these metabolic experiments are compelling that metabolic and cardiotoxic considerations are at least a necessary, if not sufficient, mechanism of action in experimental bupivacaine toxicity. This, in concert with the data on direct cardiotoxic effects, is particularly important in the clinical development of ILE as antidote, as it suggests that pharmacokinetic testing alone will tend to incompletely evaluate the potential for antidotal action of ILE. Metabolic factors may furthermore hold differential importance depending on the toxic compound.

#### **Ion channel modulation theory**

Free fatty acids, the levels of which increase with ILE, are known to have effects on both sodium and calcium ion channel function. Arachidonic, linoleic and linolenic acid all increased calcium currents through activated calcium channels in isolated guinea pig cardiac myocytes [50]. This effect appears to be directly on the channel, not modulated by any cellular second messenger system. Such an effect could be particularly important in ameliorating toxicity from calcium channel blockers, and could potentially be responsible for the short, direct cardiotoxic effect seen with ILE.

Mottram and colleagues [51] demonstrated that stearic acid partially antagonises cultured human voltage-gated sodium channels. This antagonist effect was shown experimentally to partially reverse the sodium channel antagonism seen with bupivacaine. Nadrowitz and colleagues [52] have also demonstrated partial reversal of bupivacaine-induced sodium channel antagonism on the Nav15 sodium channel, known for particular tropism with bupivacaine, with lipid application in cultured human kidney cells. Notably, in cases where lipid emulsion has been reported as having a positive outcome as an antidote, sodium channel antagonists are prominent intoxicants [18-22], and very rapid resolution of QRS duration is often reported.

## Clinical use

### Human trials

Few investigators have studied ILE in human populations. Taftachi and colleagues [53] reported the use of a lipid emulsion preparation in a randomised trial evaluating the effect on conscious state in drug-induced coma. In addition to standard supportive care, 15 patients were given an infusion of 10 ml/kg 10 % lipid emulsion. A statistically significant increase in Glasgow Coma Scale (GCS) of 2 points was seen in the ILE group. No reported differences were seen for rates of intubation (the primary powered endpoint) or time to extubation. This study has a number of methodological flaws limiting generalisability, including absence of a control solution, and no blinding in acquisition of key study metrics (GCS). Additionally, the study tested a number of endpoints without statistical correction for repeat analysis. Perhaps the greatest contribution of this work is in demonstrating that trials involving ILE in toxicology are feasible.

Gil and colleagues [54] evaluated the effect of ILE on glyphosate intoxication. After a positive case report, their institution began treating glyphosate intoxication with ILE along with supportive care from January 2012. A two-tiered approach to ILE administration was taken, with those ingesting less than 100 ml of herbicide thought to be at lesser risk of toxicity and given 20 ml/hour of 20 % lipid emulsion, and those ingesting more than 100 ml of herbicide treated with a load of 500 ml of 20 % lipid emulsion over 2 to 3 hours and then maintained on 42 ml/hour for the next 24 hours. Historical controls were taken from the previous 2 years of practice, matched for volume and timing of ingestion. Twenty-two cases and controls were compared, with 13 higher dose intoxicant patients in each group. No hypotension or arrhythmia was seen in the ILE-treated group versus rates of 40.9 % (hypotension) and 22.7 % (arrhythmia) in the control group. These differences reached statistical significance. The preponderance of hypotension and arrhythmia was seen in controls who ingested higher doses of intoxicant. Additionally, death (one case) and acute kidney injury (three cases) were seen only in the control group, and the rate of respiratory failure was lower in the ILE group (14 % versus 32 %), although these differences did not reach statistical significance. It is considered most likely that surfactants associated with the herbicide are responsible in large part for toxic action, and the authors postulated some sink mechanism may have been in action to ameliorate toxicity.

### Case series

The LIPAEMIC investigators reported 48 cases of use of ILE where details of intoxicant, treatment and outcome

were entered into an online registry. Complete capture of all cases treated in contributing centres was unlikely based on declining reporting rates over the time of data collection, meaning that inherent positive publication bias in case reports and series may still have been acting on this dataset. Increases were seen over a short time-span in both GCS in cases where lipid was used for altered conscious state (median GCS increasing from 4 to 8 over 30 minutes) and systolic blood pressure in shocked patients (median systolic pressure increasing from 70 to 90 mmHg over 30 minutes). One serious complication (bronchospasm) and two minor adverse effects were recorded. Given the nature of data collection, these results hold significance as contributors to hypothesis generation [55].

The ToxIC consortium reported a case series of nine uses of ILE from three tertiary referral centres [56]. Indications for use were post-cardiac arrest or refractory shock defined as circulatory compromise requiring the use of more than one vasopressor. Five of the nine patients survived, which was considered a positive outcome for ILE.

Three case series have been reported as conference abstracts. The Washington poisons centre reported five cases of use [57]: bupivacaine toxicity (asystole), and carbamazepine, hydroxychloroquine, flecainide and bupropion toxicity (seizures and hypotension). All cases were associated with clinical resolution of acute effects. Kapadia and colleagues [58] reported two cases of tricyclic antidepressant toxicity refractory to maximal therapy including alkalinisation and hypertonic saline whose clinical course improved after ILE. Jovic-Stosic and colleagues [59] reported a series of nine uses of ILE where the indication for use was poor response to vasopressors in a series of patients intoxicated with a lipophilic toxin. Increases in blood pressure and GCS, reported as occurring in all patients, were not quantified. A decrease in free verapamil concentration was described in one patient after ILE, with this same patient also exhibiting evidence of acute respiratory distress syndrome.

### Case reports

Two recent publications have summarised individual cases reported in the literature [8,10]. Case report data can be instructional in offering insights into therapies, and are particularly useful when outlining an 'all or nothing' type clinical situation. The significant limitation of such analyses is that for any effect published - both positive and negative - it is not known how many unpublished cases were treated. The absence of an accurate numerator significantly limits the generalisability of such collections of cases. With this as a major caveat, the review of Waring [10] found that there was reported improvement in 51 of 76 cases following administration

of ILE to treat poisoning (28 % of reported cases being LAST, 26 % being cardiovascular drugs, 25 % psychotropic agents and 11 % antiepileptic).

## Controversies

### Porcine models in lipid resuscitation

Studies investigating ILE as antidote that report negative results in animal models have mainly used the porcine model. Swine are known to be more prone to complement-mediated allergic type reactions with liposomal formulations, and this may be important in negative studies involving ILE. Weinberg and Rubinstein [60] surveyed all the authors of papers using the porcine model for ILE/antidote research and found a majority noted skin discoloration in the ILE-treated subjects consistent with such an anaphylactoid phenomenon. Two of 10 lipid treated pigs in a protocol investigating amitriptyline distribution required adrenaline boluses, despite baseline haemodynamics having returned to normal before study treatment and end-myocardial levels of amitriptyline being lower in the lipid-treated group [36]. What data are available on ILE as antidote do not appear to indicate that such reactions have occurred in humans.

### Vasopressor coadministration with intravenous lipid emulsion in local anaesthetic systemic toxicity

Literature reports of vasopressor administration in concert with ILE-based resuscitation from local anaesthetic induced cardiac arrest in animal models have returned conflicting findings. In 2009, Hiller and colleagues [61] demonstrated that epinephrine impaired resuscitation from bupivacaine-induced asystole in rats in a dose-dependent fashion. Epinephrine injection was associated with elevated serum lactate, acidosis, and lesser haemodynamic recovery. Similarly, in earlier work Weinberg and colleagues [62] demonstrated the superiority of ILE over both epinephrine and a vasopressin/epinephrine combination [63] in rodent models of bupivacaine-induced cardiac arrest. Conversely, Mayr and colleagues [64] demonstrated superior recovery with vasopressors alone in a swine model of bupivacaine-induced cardiac arrest; albeit induction of cardiac arrest was accompanied by significant hypoxia. Mauch and colleagues [65] furthermore reported lesser recovery from bupivacaine-induced shock with ILE alone compared with adrenaline, and greater return of spontaneous circulation and survival in piglets receiving adrenaline with or without ILE in bupivacaine-induced cardiac arrest. Administration of high dose (100 mcg/kg) adrenaline in concert with ILE in bupivacaine-induced cardiac arrest has almost universally resulted in deleterious outcome in animal models. What appears clear is that avoidance of hypoxia (known to exacerbate local anaesthetic toxicity), and ensuring

adequacy of cardiopulmonary resuscitation (and thereby coronary perfusion) is essential in effecting recovery. Omission of vasopressors, and adrenaline in particular, from resuscitation algorithms in LAST at this juncture remains controversial.

### Potential interaction with other resuscitation drugs

The generic nature of the sink hypothesis in ILE-based resuscitation from toxin-induced cardiac arrest has led some to question potential interaction with therapeutically administered lipophilic drugs. It would seem apparent that any effect on redistribution of toxic agents might also likewise affect agents administered therapeutically. ILE has been shown to sequester amiodarone in plasma, and ameliorate its hypotensive action when given in overdose in whole pigs [32]. The clinical effect of potential ILE-mediated pharmacokinetic modulation on therapeutically administered pharmaceuticals, however, remains uncertain. There are no direct published data on the relative roles of ILE and extracorporeal life support, with decisions to do with the use of ILE when extracorporeal life support is available in a timely fashion being necessarily based on clinical judgement.

### Enteric overdose

In keeping with the pharmacokinetic theory of ILE's mechanism, increased gastrointestinal absorption of lipophilic intoxicant might be predicted with ILE use as blood with increased affinity for highly soluble xenobiotics perfuses intestinal mucosa. ILE administration early in the course of enteric overdose may thereby paradoxically serve to increase gut absorption and speed development of systemic toxicity. While data in support of this are still emerging [42-44], significant caution should be exercised when considering ILE administration early in the course of life-threatening enteric overdose and steps should be taken prior to use of ILE to ensure absorption is minimised.

### Safety

Administration of ILE for its antidotal effect remains an 'off-label' indication. Much of what is known about ILE toxicity is derived from historic studies of use in parenteral nutrition situations. When administered for this indication, allergic phenomena, pancreatitis, induced bacteraemia, fat embolism, and myocardial failure are possible. Few reports of adverse events when administered in the context of life-threatening poisoning exist, with hyperamylasaemia [66], and adult respiratory distress syndrome being reported [5]. Lipaemia-induced impairment in laboratory processing [67] may hold considerable clinical significance, particularly for patients for whom laboratory data are pertinent to management, such as alkalinised tricyclic toxic patients. Early toxicity evaluation in rodents demonstrating a median lethal dose (LD50) of 67.72 ml/kg

when administered as bolus therapy seemingly provides for a wide therapeutic margin [68]. Further reporting of safety data is nevertheless required before final safety recommendations can be formalised.

### Clinical implications

The sporadic and unpredictable nature of LAST renders randomised controlled study of ILE in this setting difficult to impossible. The level of evidence available - animal models and case data - is supportive of effect and not likely to be increased. Reflecting this, ILE has been incorporated into LAST practice guidelines of governing bodies for anaesthetists worldwide [14].

Typical administration regimes recommend initial bolus injection of 1.5 ml/kg 20 % lipid emulsion followed by an infusion of 15 ml/kg/hour with accommodation for additional boluses to be given at 5 minute intervals. A recommendation not to exceed 12 ml/kg ILE has been proposed. Defining maximum length of treatment has not been explored in depth, although there is an isolated reported case where low dose lipid was used for some days [69].

Recommendation of ILE use in non-local anaesthetic drug poisoning remains controversial. While the present review outlines that the level of evidence in this area is evolving, the weight of evidence remains the same as in the field of local anaesthetics. Such a level of evidence can rationally be extended to the clinical situation of the patient *in extremis*, but extending any recommendation beyond this situation would require further human study. Furthermore, the pharmacokinetic consideration for ILE potentially exacerbating toxicity early in the course of enteric overdose necessitates proceeding with caution. ILE has been suggested as reasonable by the American College of Medical Toxicology, American Heart Association, and European Resuscitation Council for patients exhibiting intractable haemodynamic instability, or overt arrest, secondary to lipophilic drug toxicity that has proven refractory to available therapies. In this instance administration of ILE in accord with guidelines for use in LAST appears reasonable. It is the opinion of the authors that, at present, ILE utilisation for the purpose of reversal of drug-induced coma cannot be recommended outside the confines of a randomised clinical trial.

### Future research

Human randomised trials are possible in this field and necessary to evaluate whether ILE has a more general role in treatment of intoxicated patients. Registry data aimed at capture of all instances of ILE application are also required to determine an accurate denominator of ILE use, such that clinical performance characteristics may be inferred. Similarly, safety data in humans cannot

be derived unless all cases of ILE use and outcomes are collated to central registries as significant adverse events may occur rarely and require many thousands of uses to identify.

Basic science experimentation is furthermore required to delineate optimal doses and formulations of ILE for human application. Research exploring the utility of liposomal detoxification vesicles has proven informative, with engineered liposomes demonstrating ability to sequester lipophilic toxins with far greater affinity than standard ILE *in vitro* [70]. Subsequent use in animal models has shown the ability of such formulations to effect meaningful recovery [71].

### Conclusion

Recent advances in understanding the mechanism of ILE treatment in poisoning suggest ion channel, metabolic and cardiotoxic effects are of importance along with the more frequently quoted pharmacokinetic (sink) theory. While the evidence base for ILE use in acute drug intoxication is evolving, the present evidence supports use of ILE only in LAST and in lipophilic cardiotoxin intoxication when there is an immediate threat to life, and other therapies have proven ineffective.

### Abbreviations

GCS: Glasgow Coma Scale; ILE: Intravenous lipid emulsion; LAST: Local anaesthetic systemic toxicity.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Critical Care, Tamworth Rural Referral Hospital, Tamworth, NSW 2340, Australia. <sup>2</sup>Waikato Hospital, Pembroke St, Hamilton 3204, New Zealand.

Published online: 30 July 2014

### References

1. Weinberg G, VadeBoncouer T, Ramaraju G, Garcia-Amaro M, Cwik M: Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. *Anesthesiology* 1998, **88**:1071-1075.
2. Weinberg G, Ripper R, Feinstein D, Hoffman W: Lipid emulsion infusion rescues dogs from bupivacaine induced cardiac toxicity. *Reg Anesth Pain Med* 2003, **28**:198-202.
3. Krieglstein J, Meffert A, Niemeyer D: Influence of emulsified fat on chlorpromazine availability in rabbit blood. *Experientia* 1974, **15**:924-926.
4. Rosenblatt M, Abel M, Fischer G, Itzkovich C, Eisenkraft J: Successful use of a 20 % lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. *Anesthesiology* 2006, **105**:217-218.
5. Sirianni A, Osterhoudt K, Calello D, Muller AA, Waterhouse MR, Goodkin MB, Weinberg GL, Henretig FM: Use of Intralipid in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. *Ann Emerg Med* 2007, **51**:412-415.
6. Harvey M, Cave G: Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systematic review. *Acad Emerg Med* 2009, **16**:815-824.
7. Leelach R, Bern S, Oswald S, Weinberg G: Intravenous lipid emulsion in clinical toxicology. *Scand J Trauma Resusc Emerg Med* 2010, **18**:51-59.
8. Jamaty C, Bailey B, Larocque A, Notebaert E, Sanogo K, Chauny JM: Lipid emulsions in the treatment of acute poisoning: a systematic review of human and animal studies. *Clin Toxicol* 2010, **48**:1-27.

9. Cave G, Harvey M, Graudins A: **Intravenous lipid emulsion as antidote: a summary of published human experience.** *Emerg Med Australas* 2011, **23**:123–141.
10. Waring S: **Intravenous lipid administration for drug-induced toxicity: a critical review of the existing data.** *Expert Rev Clin Pharmacol* 2012, **5**:437–444.
11. Weinberg G, Ripper R, Murphy P, Edelman LB, Hoffman W, Strichartz G, Feinstein DL: **Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicity in the isolated rat heart.** *Reg Anesth Pain Med* 2006, **31**:296–303.
12. Chen Y, Xia Y, Liu L, Shi T, Shi K, Wang Q, Chen L, Papadimos TJ, Xu X: **Lipid emulsion reverses bupivacaine induced asystole in isolated rat hearts: concentration response and time response relationships.** *Anesthesiology* 2010, **113**:1320–1325.
13. Shi K, Xia Y, Wang Q, Wu Y, Dong X, Chen C, Tang W, Zhang Y, Luo M, Wang X, Papadimos TJ, Xu X: **The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats.** *Anesth Analg* 2013, **116**:804–809.
14. The Association of Anaesthetists of Great Britain and Ireland: *Guidelines for the Management of Severe Local-Anaesthetic Toxicity.* <http://www.aagbi.org/publications/guidelines/docs/latotoxicity07.pdf>.
15. Yoav G, Odelia G, Shaltiel C: **A lipid emulsion reduces mortality from clomipramine overdose in rats.** *Vet Hum Toxicol* 2002, **44**:30.
16. Bania T, Chu J: **Hemodynamic effect of intralipid in amitriptyline toxicity.** *Acad Emerg Med* 2006, **13**(S1):117.
17. Harvey M, Cave G: **Intralipid outperforms sodium bicarbonate in a rabbit model of clomipramine toxicity.** *Ann Emerg Med* 2007, **49**:178–185.
18. Boegevig S, Rothe A, Tfelt-Hansen J, Hoegberg LC: **Successful reversal of life threatening cardiac effect following dosulepin overdose using intravenous lipid emulsion.** *Clin Toxicol* 2011, **49**:337–339.
19. ten Tusscher BL, Beishuizen A, Girbes AR, Swart EL, van Leeuwen RW: **Intravenous fat emulsion therapy for intentional propafenone intoxication.** *Clin Toxicol* 2011, **49**:701.
20. Mousso PE, Marhar F, Minville V, Vallé B, Dehours E, Bounes V, Ducassé JL: **Use of intravenous lipid emulsion for the treatment of a voluntary intoxication of flecainide with refractory shock.** *Clin Toxicol* 2011, **49**:514.
21. Arora NP, Berk WA, Aaron CK, Williams KA: **Usefulness of intravenous lipid emulsion for cardiac toxicity from cocaine overdose.** *Am J Cardiol* 2013, **111**:445–447.
22. Carriero S, Blum J, Hack JB: **Pretreatment with intravenous lipid emulsion reduces mortality from cocaine toxicity in a rat model.** *Ann Emerg Med* 2014, **64**:32–37.
23. Cave G, Harvey M, Quinn P, Heys D: **Hypertonic sodium bicarbonate versus intravenous lipid emulsion in a rabbit model of intravenous flecainide toxicity: no difference, no sink.** *Clin Toxicol* 2013, **51**:394–397.
24. Jakkala-Saibaba R, Morgan PG, Morton GL: **Treatment of cocaine overdose with lipid emulsion.** *Anaesthesia* 2011, **66**:1168–1170.
25. Tebbutt S, Harvey M, Nicholson T, Cave G: **Intralipid prolongs survival in a rat model of verapamil toxicity.** *Acad Emerg Med* 2006, **13**:134–139.
26. Bania T, Chu J, Perez E: **Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline.** *Acad Emerg Med* 2007, **14**:105–111.
27. Perez E, Bania T, Medlej K, Chu J: **Determining the optimal dose of intravenous fat emulsion for the treatment of severe verapamil toxicity in a rodent model.** *Acad Emerg Med* 2009, **15**:1284–1289.
28. Bania T, Chu J, Wesolowski M: **The hemodynamic effect of Intralipid on propranolol toxicity.** *Acad Emerg Med* 2006, **13**(S1):109.
29. Harvey M, Cave G: **Intralipid infusion ameliorates propranolol induced hypotension in rabbits.** *J Med Toxicol* 2008, **4**:71–76.
30. Weinberg G, Di Gregorio G, Hiller D, Hewett A, Sirianni A: **Reversal of haloperidol induced cardiac arrest by using lipid emulsion.** *Ann Int Med* 2009, **19**:737–738.
31. Moshiri M, Vahabzadeh M, Mohammadpour A, Hosseinzadeh H: **Evaluation of intravenous lipid emulsion on haloperidol induced hypotension in rabbits.** *Toxicol Ind Health* 2014, **30**: [Epub ahead of print].
32. Niiya T, Litonius E, Petaja L, Neuvonen P, Rosenburg P: **Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs.** *Ann Emerg Med* 2010, **56**:402–408.
33. French D, Smollin C, Ruan W, Wong A, Drasner K, Wu A: **Partition constant and volume of distribution as predictors of clinical efficacy of lipid rescue for toxicologic emergencies.** *Clin Toxicol* 2011, **49**:801–809.
34. Harvey M, Cave G: **Correlation of plasma and peritoneal diastylate clomipramine concentration with hemodynamic recovery after Intralipid infusion in rabbits.** *Acad Emerg Med* 2009, **16**:151–156.
35. Litonius E, Niiya T, Neuvonen P, Rosenburg P: **No antidotal effect of intravenous lipid emulsion in experimental amitriptyline intoxication despite significant entrapment of amitriptyline.** *Basic Clin Pharmacol Toxicol* 2012, **110**:378–383.
36. Heinonen J, Litonius E, Backman J, Neuvonen P, Rosenburg P: **Intravenous lipid emulsion entraps amitriptyline into plasma and can lower its brain concentration - an experimental intoxication study in pigs.** *Basic Clin Pharmacol Toxicol* 2013, **113**:193–200.
37. Minton N, Goode A, Henry J: **The effect of a lipid suspension on amitriptyline disposition.** *Arch Toxicol* 1987, **60**:467–469.
38. Litonius E, Tarkkila P, Neuvonen P, Rosenburg P: **Effect of intravenous lipid emulsion on bupivacaine plasma concentration in humans.** *Anaesthesia* 2012, **67**:600–605.
39. French D, Armenian P, Ruan W, Wong A, Drasner K, Olson KR, Wu AH: **Serum verapamil concentrations before and after intralipid therapy during treatment of an overdose.** *Clin Toxicol* 2011, **49**:340–344.
40. Harvey M, Cave G: **Case report: successful lipid resuscitation in a multi-drug overdose with predominant tricyclic antidepressant toxidrome.** *Int J Emerg Med* 2012, **5**:5–8.
41. Kazemi A, Harvey M, Cave G, Lahner D: **The effect of a lipid emulsion on depth of anaesthesia following thiopental administration to rabbits.** *Anaesthesia* 2011, **66**:373–378.
42. Perichon D, Turfus S, Gerostamoulos D, Graudins A: **An assessment of the in vivo effects of intravenous lipid emulsion on blood drug concentration and haemodynamics following oro-gastric amitriptyline overdose.** *Clin Toxicol* 2013, **51**:208–215.
43. Harvey M, Cave G, Shaw T: **Effect of intravenous lipid emulsion and octreotide on enteric thiopentone absorption: a pilot study.** *Clin Toxicol* 2013, **51**:117–118.
44. Dunn C, Bird S, Gaspari R: **Intralipid fat emulsion decreases respiratory failure in a rat model of parathion exposure.** *Acad Emerg Med* 2012, **19**:504–509.
45. Fettiplace M, Ripper R, Lis K, Lin B, Lang J, Zider B, Wang J, Rubinstein I, Weinberg G: **Rapid cardiotoxic effects of lipid emulsion infusion.** *Crit Care Med* 2013, **41**:156–162.
46. Stehr S, Ziegeler J, Pexa A, Oertel R, Deussen A, Koch T, Hübler M: **The effects of lipid infusion on myocardial function and bioenergetics in l-bupivacaine toxicity in the isolated rat heart.** *Anesth Analg* 2007, **104**:186–192.
47. Fettiplace M, Akpa B, Ripper R, Zider B, Lang J, Rubinstein I, Weinberg G: **Resuscitation with lipid emulsion: dose-dependent recovery from cardiac pharmacotoxicity requires a cardiotoxic effect.** *Anesthesiology* 2014, **120**:915–925.
48. Partownavid P, Umar S, Li J, Rahman S, Eghbali M: **Fatty-acid oxidation and calcium homeostasis are involved in the rescue of bupivacaine induced cardiotoxicity by lipid emulsion in rats.** *Crit Care Med* 2012, **40**:2431–2437.
49. Bania T, Chu J, Lyon T, Yoon J: **The role of cardiac free fatty acid metabolism in verapamil toxicity treated with intravenous fat emulsions.** *Acad Emerg Med* 2007, **14**:196–197.
50. Huang J, Xian H, Bacaner M: **Long chain fatty acids activate calcium channels in ventricular myocytes.** *Proc Natl Acad Sci U S A* 1992, **89**:6452–6456.
51. Mottram A, Valdivia C, Makielski J: **Fatty acids antagonize bupivacaine induced I (NA) blockade.** *Clin Toxicol* 2011, **49**:729–733.
52. Nadrowitz F, Stoetzer C, Foadi N, Ahrens J, Wegner F, Lampert A, Koppert W, de la Roche J, Leffler A: **The distinct effects of lipid emulsions used for lipid resuscitation on gating and bupivacaine induced inhibition of the cardiac sodium channel Nav1.5.** *Anesth Analg* 2013, **117**:1101–1108.
53. Taftachi F, Sanaei-Zadeh H, Sepehrian B, Zamani N: **Lipid emulsion improves Glasgow coma scale and decreases blood glucose level in the setting of acute non-local anesthetic drug poisoning - a randomised controlled trial.** *Eur Rev Med Pharmacol Sci* 2012, **16**:38–42.
54. Gil H, Park J, Park S, Hong S: **Effect of intravenous lipid emulsion in patients with acute glyphosate intoxication.** *Clin Toxicol* 2013, **51**:767–771.
55. Cave G, Harvey M, Willer J, Uncles D, Meek T, Picard J, Weinberg G: **LIPAEMIC Report: results of clinical use of intravenous lipid emulsion in drug toxicity reported to an online lipid registry.** *J Med Toxicol* 2014, **10**:133–142.

56. Geib A, Liebelt E, Manini A: Toxicology Investigators Consortium (ToxIC): **Clinical experience with intravenous lipid emulsion for drug induced cardiovascular collapse.** *J Med Toxicol* 2012, **8**:10–14.
57. Hurley W, Hanlon P: **Lipid emulsion as antidote at the Washington Poisons Centre: use in carbamazepine, flecainide, hydroxychloroquine, bupivacaine and bupropion.** *Clin Toxicol* 2009, **47**:729–730.
58. Kapadia K, Al Duaj N, Ganetsky M, Burke L, Horn E, Rosen C: **Case series of severe TCA toxicity treated with intravenous fat emulsion.** *Clin Toxicol* 2010, **48**:612.
59. Jovic-Stosic J, Putic V, Djordjevic S, Vukcevic N, Vucinic S, Ercegovic G: **Lipid emulsion in treatment of cardiovascular collapse in acute poisoning.** *Clin Toxicol* 2013, **51**:288.
60. Weinberg G, Rubinstein I: **Pig in a poke: species specificity in modelling lipid resuscitation.** *Anesth Analg* 2012, **114**:907–909.
61. Hiller D, Gregorio G, Ripper R, Kelly K, Massad M, Edelman L, Edelman G, Feinstein DL, Weinberg GL: **Epinephrine impairs lipid resuscitation from bupivacaine overdose: a threshold effect.** *Anesthesiology* 2009, **111**:498–505.
62. Weinberg G, Di Gregorio G, Ripper R, Kelly K, Massad M, Edelman L, Schwartz D, Shah N, Zheng S, Feinstein DL: **Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose.** *Anesthesiology* 2008, **108**:907–913.
63. Di Gregorio G, Schwartz D, Ripper R, Kelly K, Feinstein DL, Minshall RD, Massad M, Ori C, Weinberg GL: **Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin induced cardiac arrest.** *Crit Care Med* 2009, **37**:993–999.
64. Mayr V, Mitterschiffhaller L, Neurater A, Gritsch C, Wenzel V, Müller T, Luckner G, Lindner KH, Strohmenger HU: **A comparison of the combination of epinephrine and vasopressin with lipid emulsion in a porcine model of asphyxial cardiac arrest after intravenous injection of bupivacaine.** *Anesth Analg* 2008, **106**:1566–1571.
65. Mauch J, Martin J, Spielmann N, Bettschart-Wolfensberger R, Weiss M: **Comparison of epinephrine vs lipid rescue to treat severe local anesthetic toxicity - an experimental study in piglets.** *Paediatr Anaesth* 2011, **21**:1103–1108.
66. Bucklin M, Gordodetsky R, Wiegand T: **Prolonged lipemia and pancreatitis due to extended infusion of lipid emulsion in bupropion overdose.** *Clin Toxicol* 2013, **51**:896–898.
67. Dmieski G: **A commentary on the effect of lipid emulsions on pathology testing.** *Anaesthesia* 2009, **64**:1033–1036.
68. Hiller D, Di Gregorio G, Kelly K, Ripper R, Edelman L, Boumendjel R, Drasner K, Weinberg GL: **Safety of high volume lipid emulsion: a first approximation of LD50 in rats.** *Reg Anesth Pain Med* 2010, **35**:140–144.
69. Agarwala R, Ahmed S, Weigand T: **Prolonged use of intravenous lipid emulsion in a severe tricyclic antidepressant overdose.** *J Med Toxicol* 2014, **10**:210–214.
70. Howell B, Chauhan A: **A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man.** *J Pharm Sci* 2010, **99**:3601–3619.
71. Forster V, Luciani P, Leroux J: **Treatment of calcium channel blocker induced cardiovascular toxicity with drug scavenging liposomes.** *Biomaterials* 2012, **33**:3578–3585.

doi:10.1186/s13054-014-0457-5

**Cite this article as:** Cave and Harvey: Should we consider the infusion of lipid emulsion in the resuscitation of poisoned patients?. *Critical Care* 2014 **18**:457.